A Phase I study of the ADAM-10 inhibitor, INCB7839 in children with recurrent/progressive high-grade gliomas to target microenvironmental neuroligin-3

Abstract and Schema

This is a multicenter phase 1 trial of INCB7839 for children with recurrent or progressive high-grade gliomas, including, but not limited to, diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs), after upfront therapy.

INCB7839 is an inhibitor of the ADAM (A Disintegrin and Metalloprotease) 10 and 17 proteases. Neuronal activity regulates glioma growth through neuroligin-3 (NLGN3). ADAM 10 is the protease responsible for NLGN3 release into the tumor microenvironment and represents a promising therapeutic target.

Pre-clinical studies of INCB7839 in patient-derived pediatric high-grade gliomas (GBM and DIPG) revealed that INCB7839 inhibits pediatric high-grade glioma growth and improves overall survival. In vivo testing also demonstrated that INCB7839 penetrates brain tissue sufficient to achieve its pharmacodynamic effect of ADAM10 inhibition. Further pre-clinical studies in other animals revealed minimal toxicity, including non-adverse to mild increases in serum hepatobiliary enzymes, protein, calcium, cholesterol values, along with minimal decreases in RBC mass parameters; all parameters recovered.

INCB7839 has been evaluated in Phase I and Phase II clinical trials for previously treated solid tumors and breast cancer. Of the adverse events (AEs) noted, the majority were mild-to-moderate in severity, the most frequent being fatigue, nausea, anorexia, diarrhea, emesis, abdominal pain, anemia and constipation. The dose-limiting toxicity for monotherapy with INCB7839 in Phase I clinical trials was declared to be deep venous thrombosis (DVT). Out of 41 patients, there was a total of 9 thrombotic events including mild superficial thrombophlebitis (n=1), DVT (n=4), vena cava thrombosis with renal insufficiency in a patient with squamous cell cancer of the head and neck (n=1), atrial thrombosis in patient with breast cancer (n=1), and pulmonary embolism in patients with hormone-refractory prostate cancer (n=2). Overall, INCB7839 does exhibit a pro-coagulant effect in some adult patients, resulting in an increased incidence of DVT, whether used alone or in combination. The mechanism of this effect is unknown, and there is no clear relationship between the frequency of thrombosis and the dose administered.

The primary objectives of this study are to (1) evaluate the safety and tolerability of INCB7839 administered daily to children with recurrent/progressive high-grade gliomas; (2) determine the maximum tolerated dose (MTD) and/or recommended phase II (RP2D) dose of INCB7839; (3) characterize the pharmacokinetics of INCB7839.

The adult RP2D is 200 mg orally (PO) twice a day (BID). Given this recommended dose, we propose to test the pediatric equivalent based on a typical adult of 1.67m²: 120 mg/m². Thus, this clinical trial will start at 120 mg/m² and de-escalate to 80 mg/m² if it is not tolerable. INCB7839 will be administered orally, twice a day each day for 28-day cycles. Patients will be provided with
a Medication Diary for INCB7839 and asked to bring the diary as well as the remaining pill bottles with them to each appointment. Treatment may continue up to 26 courses (approximately 2 years) in the absence of disease progression or unacceptable toxicity. The table below lists the proposed dose levels to be studied:

<table>
<thead>
<tr>
<th>Dose Level</th>
<th>Dose of INCB7839 (mg/m²/dose, PO, BID)</th>
<th>BSA Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level 0</td>
<td>80 mg/m²/dose BID</td>
<td>0.55-2.80 m²</td>
</tr>
<tr>
<td>Level 1*</td>
<td>120 mg/m²/dose BID</td>
<td>0.70-2.50 m²</td>
</tr>
</tbody>
</table>

*Starting Dose (Adult RP2D)
1 OBJECTIVES

1.1 PRIMARY OBJECTIVES
1.1.1 To evaluate the safety and tolerability of INCB7839 in children with recurrent/progressive high-grade gliomas, including diffuse intrinsic pontine glioma (DIPG), diffuse midline glioma (DMG), glioblastoma (GBM) and anaplastic astrocytoma.
1.1.2 To estimate the maximum tolerated dose (MTD) and/or recommend Phase II dose (RP2D) of INCB7839 administered orally in children with recurrent/progressive high-grade glioma.
1.1.3 To characterize the plasma pharmacokinetics of INCB7839 administered on this schedule in children with recurrent/progressive high-grade glioma.

1.2 SECONDARY OBJECTIVES
1.2.1 To make a preliminary assessment of efficacy via objective response and overall survival in children with recurrent/progressive high-grade glioma.

1.3 EXPLORATORY OBJECTIVES
1.3.1 To assess and monitor ADAM10 inhibition of HER2 (human epidermal growth factor receptor 2) extracellular domain in serum, and explore potential correlation with patient outcome.
1.3.2 To assess and monitor ADAM10 inhibition of neuroligin-3 (NLGN3) in cerebral spinal fluid.
1.3.3 To characterize the pharmacokinetics of INCB7839 in cerebrospinal fluid.

2 PATIENT SELECTION

All subjects must meet the following inclusion and exclusion criteria. No exceptions will be given. Imaging studies to establish eligibility must be done within three weeks prior to enrollment. All other clinical evaluations to establish eligibility must be done within 7 days prior to enrollment.

2.1 INCLUSION CRITERIA

2.1.1 Histologic diagnosis
Patients with recurrent/progressive high-grade gliomas, as defined by progressive neurologic abnormalities or worsening neurologic status not explained by causes unrelated to tumor progression (e.g., anticonvulsant or corticosteroid wean, electrolyte disturbances, sepsis, hyperglycemia, etc.), OR a 25% increase in the bi-dimensional measurement, taking as a reference the smallest disease measurement recorded since diagnosis utilizing the MRI sequence best demonstrating tumor, OR the appearance of a new/metastatic tumor lesion since diagnosis.

- Eligible diagnoses include but are not limited to the following: diffuse intrinsic pontine glioma (DIPG), H3K27M-mutant diffuse midline glioma (DMG), glioblastoma multiforme, anaplastic astrocytoma and anaplastic oligodendroglioma. Spinal cord tumors are eligible with pathologic confirmation of the above.
- Please note: patients with a radiographically typical DIPG at diagnosis, defined as a
tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons, are eligible without histologic confirmation.

- Patients with pontine lesions that do not meet these radiographic criteria will be eligible if there is histologic confirmation of pontine glioma WHO II-IV.
- Patients with diffuse or multi-focal disease are eligible; patients with leptomeningeal spread are eligible.

2.1.2 Age
Patient must be ≥ 3 but ≤ 21 years of age at the time of enrollment.

2.1.3 BSA
Patients must have a BSA ≥ 0.70-2.50 m² for dose 120 mg/m²/dose BID.
Patients must have a BSA ≥ 0.55-2.80 m² for dose 80 mg/m²/dose BID (Patients who have BSA 0.55-1.00 m² will only receive 100 mg AM dose).

2.1.4 Ability to Swallow
Patient must be able to swallow tablets whole.

2.1.5 Measurable disease
Patient must have measurable disease in two dimensions on MRI to be eligible (as defined within the protocol, section 12.1.2).

2.1.6 Prior Therapy
Patients must have recovered from the acute treatment-related toxicities (defined as ≤ grade 1) of all prior chemotherapy, immunotherapy, or radiotherapy prior to enrollment on this study.

2.1.6.1 Chemotherapy
Patients must have received their last dose of known myelosuppressive anticancer therapy at least 21 days prior to enrollment or at least 42 days if nitrosourea.

2.1.6.2 Investigational/Biologic Agent
- Biologic or investigational agent (anti-neoplastic):
  Patient must have recovered from any acute toxicity potentially related to the agent and received their last dose of the investigational or biologic agent ≥ 7 days prior to study enrollment.
  - For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur.
- Monoclonal antibody treatment and agents with known prolonged half-lives:
  Patient must have recovered from any acute toxicity potentially related to the agent and received their last dose of the agent ≥ 28 days prior to study enrollment.
- Immunotherapies:
  Patients who have received checkpoint inhibitors or other immunotherapies with a known potential for pseudoprogression and who have assumed tumor progression must be at least 3 months from prior immunotherapy AND have at least two MRI scans at least 4 weeks apart demonstrating further progression OR have a biopsy to confirm tumor progression OR have new site(s) of disease.
2.1.6.3 Radiation
Patients must have had their last fraction of:
- Craniospinal irradiation, whole brain radiation, total body irradiation or radiation to ≥ 50% of pelvis or spine ≥ 42 days prior to enrollment.
- Focal irradiation ≥ 14 days prior to enrollment.
- Local palliative irradiation to site other than primary tumor progression site ≥ 14 days prior to enrollment.

2.1.6.4 Stem Cell Transplant
Patient must be:
- ≥ 6 months since allogeneic stem cell transplant prior to enrollment with no evidence of active graft vs. host disease.
- ≥ 3 months since autologous stem cell transplant prior to enrollment.

2.1.7 Neurologic Status
- Patients with neurological deficits should have deficits that are stable for a minimum of 7 days prior to enrollment.
- Patients with seizure disorders may be enrolled if seizures are well controlled.

2.1.8 Performance Status
Karnofsky Performance Scale (KPS for > 16 years of age) or Lansky Performance Score (LPS for ≤ 16 years of age) assessed within two weeks of enrollment must be ≥ 50.

2.1.9 Organ Function
Patients must have adequate organ and marrow function as defined below:
- Absolute neutrophil count ≥ 1.0 x 10⁹ cells/ L
- Platelets >100 x 10⁹ cells/ L (unsupported, defined as no platelet transfusion within 7 days)
- Hemoglobin ≥ 8g/dl (may receive transfusions)
- Total bilirubin ≤ 1.5 times institutional upper limit of normal (ULN)
- ALT (SGPT) and AST (SGOT) < 3 x institutional upper limit of normal (ULN)
- Albumin ≥ 2 g/dL
- Serum creatinine based on age/gender as noted in Table 1. Patients that do not meet the criteria in Table 1 but have a 24-hour Creatinine Clearance or GFR (radioisotope or iothalamate) ≥ 70 mL/min/1.73 m² are eligible.

<table>
<thead>
<tr>
<th>Age</th>
<th>Maximum Serum Creatinine (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Male</td>
</tr>
<tr>
<td>3 to &lt; 6 years</td>
<td>0.8</td>
</tr>
<tr>
<td>6 to &lt; 10 years</td>
<td>1</td>
</tr>
<tr>
<td>10 to &lt; 13 years</td>
<td>1.2</td>
</tr>
<tr>
<td>13 to &lt; 16 years</td>
<td>1.5</td>
</tr>
<tr>
<td>≥ 16 years</td>
<td>1.7</td>
</tr>
</tbody>
</table>

The threshold creatinine values in this Table were derived from the Schwartz formula for estimating GFR (Schwartz et al. J. Peds, 106:522, 1985) utilizing child length and stature data published by the CDC.
2.1.10 Corticosteroids
Patients who are receiving dexamethasone must be on a stable or decreasing dose for at least 7 days prior to enrollment.

2.1.11 Growth Factors
Patients must be off all colony-forming growth factor(s) for at least 7 days prior to enrollment (e.g. filgrastim, sargramostim or erythropoietin). 14 days must have elapsed if patient received a long-acting formulation.

2.1.12 Pregnancy Prevention
Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study.

2.1.13 Informed Consent
The patient or parent/guardian is able to understand the consent and is willing to sign a written informed consent document according to institutional guidelines.

2.1.14 HIV Positive Patients
HIV-positive patients are eligible if the following criteria are met:
- Stable on their antiretroviral agents
- Have CD4 counts above 400/mm³
- Undetectable viral loads, and
- No need for prophylactic medications for an opportunistic infections

2.2 EXCLUSION CRITERIA

2.2.1 Pregnancy or Breast-feeding
Pregnant women or nursing mothers are excluded from this study. Female patients of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- Pregnant or breast-feeding women are excluded from this study due to risks of fetal and teratogenic adverse events as seen in animal studies.

2.2.2 Concurrent Illness
- Patients with any clinically significant unrelated systemic illness (e.g., serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), that in the opinion of the investigator would compromise the patient’s ability to tolerate protocol therapy, put them at additional risk for toxicity or would interfere with the study procedures or results.
- Patients with any other current malignancy.

2.2.3 Concomitant Medications
- Patients who are receiving any other anti-cancer, investigational or alternative (e.g. cannabinoids) drug therapy are ineligible.
2.2.4 Prisoners
Prisoners will be excluded from this study.

2.2.5 Inability to participate
Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures and study restrictions.

2.2.6 Allergy
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition.

2.2.7 Thrombosis Risk
- Patients with a known coagulopathy or bleeding disorder (e.g., von Willebrand’s disease) are not eligible.
- Patients with a history of non-central line related thrombosis or disorders that promote clotting (e.g., anti-thrombin III deficiency, Lupus anticoagulant) are not eligible.
- Significant family history of thrombosis (i.e. deep venous thrombosis or pulmonary embolus) in a first-degree relatives (i.e., parents or siblings) are not eligible.

Family history must be documented to the best extent it is known.